Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

istorical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Exalgo® is a registered trademark of Mallinckrodt LLC. CONTACTS:Investors: 

Patty Eisenhaur  

(862) 261-8141 

  Media: 

Charlie Mayr 

(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 /CNW/ - ... seized a health product being injected at Art Nails Ltd., ... which appeared to be unauthorized as it contained no labelling. All ... be authorized by Health Canada and must have approved labelling. ... that had been administered to consumers. Potential risks associated with injecting ...
(Date:3/3/2015)... , March 3, 2015 ... 356 and 240 patients respectively Publications in ... Journal of Clinical Gastroenterology highlight diagnostic value of ... China and across ... Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ) ... Diagnostics Market 2015-2019" report to their offering. ... Diagnostics market to grow at a CAGR of 8.47 ... diagnostics are IVD devices and tools used for diagnosing ... use of these devices helps in the rapid diagnosis ...
Breaking Medicine Technology:Advisory - Health product seized from Art Nails in Vancouver 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is honored ... the company as Chief Technology Officer. Mr. Dvorak will ... company, including customer-centric strategies and initiatives, and promoting continuous ... as a technology executive and visionary. Prior to joining ... including oversight of enterprise data management, analytic software development, ...
(Date:3/4/2015)... 04, 2015 In a small ceremony with ... on their new facility in New Port Richey on February ... new facility will allow the Florida drug detox facility ... drug abuse epidemic through treatment and education. “Due to our ... in the United States, we made the decision that expanding ...
(Date:3/4/2015)... 2015 i2i Systems Population Health ... Chase Brexton Health Care, a 35-year-old Maryland-based community ... Brexton provides comprehensive primary care, behavioral health and ... seven clinics in the greater Baltimore area of ... records, the organization has always focused on providing ...
(Date:3/4/2015)... March 04, 2015 Dietary supplement company ... the world’s first biocompatible copper chelate, at Natural Products ... guests the chance to gain insight into their wellness ... the Cunermuspir complex can support their individual nutritional needs, ... which is the core ingredient of the MitoSynergy product ...
(Date:3/4/2015)... 2015 The report “Vasculitis – Pipeline ... development for Vasculitis. Vasculitis is a disease that features ... vasculitis diseases is not known. Vasculitis can affect any ... symptoms. Symptoms can include fever, weight loss, tiredness, aches, ... in a limb. Vasculitis is treatable, but it is ...
Breaking Medicine News(10 mins):Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4
... the MetLife Foundation Awards for Medical Research ... today, at a scientific briefing and luncheon that honors two ... Alzheimer,s and the substances in the brain that play an ... S. Wolfe , Ph.D., professor of neurology at Harvard ...
... 18 Natural Harmony,Foods, Inc., (Pink Sheets: NHYF) is ... has succeeded in moving on to the next round ... Natural Harmony Foods was,invited to enter this prestigious annual ... to consumers each year. , ...
... Shows Five Masimo Rad-57 Pulse CO-Oximeters(TM) Detected 83 Unsuspected ... UK Reported Annual CO PoisoningsIRVINE, Calif., Feb. 18 ... Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, ... UK House of Commons All Party Parliamentary Gas Safety ...
... MinuteClinic, the pioneer and largest provider of ... that it has become a participating provider in ... is the uniformed services health care program for ... service members and their families, members of the ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced ... trial of an orally administered niacin receptor agonist drug ... its collaboration with Arena to treat atherosclerosis. Agonists of ... lipid profiles, including HDL, or the "good" cholesterol, similar ...
... - results from this trial supported entry into ... cancer program -,BELLEVILLE, ON, Feb. 18 /PRNewswire-FirstCall/ - ... technology-driven Canadian biopharmaceutical company, today announced that The ... the Phase II clinical trial results for the ...
Cached Medicine News:Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 2Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 3Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 4Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 5Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 6Health News:Natural Harmony Foods, Inc. Advances to the Next Round of America's Healthiest Food Awards 2Health News:Natural Harmony Foods, Inc. Advances to the Next Round of America's Healthiest Food Awards 3Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 2Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 3Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 4Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 5Health News:United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening by Pulse CO-Oximetry(TM) to Reduce Misdiagnosis and Prevent Deaths 6Health News:MinuteClinic Becomes Participating Provider for Health Net Federal Services/TRICARE North, Insurer for Military Families 2Health News:MinuteClinic Becomes Participating Provider for Health Net Federal Services/TRICARE North, Insurer for Military Families 3Health News:Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist 2Health News:Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4
Providing a perfect combination of capacity, speed and innovation, the Concept 400 delivers simple sophistication and new levels of comfort and convenience....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
... MARS Enduro is the ideal partner ... required before, during or directly after ... longitudinal adjustment and the filigreed construction, ... in examination, induction and operating theatre. ...
23" Top Slide with Full Table Functions for Every Procedure...
Medicine Products: